Manufacturer of Controlled Substances; Notice of Application, 44860-44861 [E7-15499]

Download as PDF 44860 Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 JeffersonDavis Highway, Alexandria, Virginia 22301; and must be filed no later than September 10, 2007. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–15553 Filed 8–8–07; 8:45 am] Drug Schedule Sufentanil (9740) .......................... Fentanyl (9801) ............................ The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 9, 2007. Dated: July 31, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–15500 Filed 8–8–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration BILLING CODE 4410–09–P Manufacturer of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 11, 2007, Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug mstockstill on PROD1PC66 with NOTICES II II Schedule N-Ethylamphetamine (1475) ........ Tetrahydrocannabinols (7370) ..... 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). 4-Methoxyamphetamine (7411) ... Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Pentobarbital (2270) ..................... Phenylacetone (8501) .................. Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... VerDate Aug<31>2005 18:25 Aug 08, 2007 I I I I I II II II II II II II II II II Jkt 211001 Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on June 11, 2007, Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance to manufacture amphetamine. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 Any bulk manufacturer who is presently, or are applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 10, 2007. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: August 1, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–15510 Filed 8–8–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 29, 2007, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following E:\FR\FM\09AUN1.SGM 09AUN1 44861 Federal Register / Vol. 72, No. 153 / Thursday, August 9, 2007 / Notices basic classes of controlled substances listed in schedule II: Drug Schedule Lisdexamfetamine (1205) ............. Remifentanil (9739) ...................... II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 9, 2007. and determined that the registration of Noramco, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Noramco, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: August 1, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–15514 Filed 8–8–07; 8:45 am] Dated: July 31, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–15499 Filed 8–8–07; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P Importer of Controlled Substances; Notice of Registration DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated April 17, 2007 and published in the Federal Register on April 30, 2007, (72 FR 21298), Noramco Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II: Schedule mstockstill on PROD1PC66 with NOTICES Raw Opium (9600) ....................... Concentrate of Poppy Staw (9670). II II The company plans to import the listed controlled substances to manufacture other controlled substances. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) VerDate Aug<31>2005 18:25 Aug 08, 2007 Jkt 211001 Dated: July 31, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–15515 Filed 8–8–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE Drug with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Penick Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to Title 21, U.S.C. 952(a) and 958(a), and in accordance with Title 21, Code of Federal Regulations (CFR) § 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. By Notice dated May 10, 2007 and published in the Federal Register on May 18, 2007, (72 FR 28077), Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II: Drug Schedule Coca Leaves (9040) ..................... Raw Opium (9600) ....................... Poppy Straw (9650) ..................... Concentrate of Poppy Straw (9670). II II II II The company plans to import the listed controlled substances to manufacture bulk controlled substance intermediates for sale to its customers. No comments or objections have been received. DEA has considered the factors in Title 21, United States Code (U.S.C.) § 823(a) and § 952(a) and determined that the registration of Penick Corporation to import the basic classes of controlled substances is consistent with the public interest and PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 Manufacturer of Controlled Substances; Notice of Registration By Notice dated March 9, 2007, and published in the Federal Register on March 23, 2007 (72 FR 13825), Sigma Aldrich Research, Biochemicals, Inc., 1– 3 Strathmore Road, Natick, Massachusetts 01760, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I: Drug Psilocybin (7437) .......................... 5-Methoxy-N,Ndiisopropyltyptamine (7439). Schedule I I The company plans on manufacturing reference standards for research purposes only. No comments or objections have been received. DEA has considered the factors in Title 21, United States Code (U.S.C.) 823(a) and determined that the registration of Sigma Aldrich Research, Biochemicals, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Sigma Aldrich Research, Biochemicals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection E:\FR\FM\09AUN1.SGM 09AUN1

Agencies

[Federal Register Volume 72, Number 153 (Thursday, August 9, 2007)]
[Notices]
[Pages 44860-44861]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-15499]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 29, 2007, Chattem 
Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, 
Tennessee 37409, made application by letter to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
following

[[Page 44861]]

basic classes of controlled substances listed in schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lisdexamfetamine (1205)....................  II
Remifentanil (9739)........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a). Any such comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537; or any being sent via 
express mail should be sent to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be 
filed no later than October 9, 2007.

    Dated: July 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-15499 Filed 8-8-07; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.